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Research Silencing of TESTIN by dense biallelic promoter 
methylation is the most common molecular event 
in childhood acute lymphoblastic leukaemia
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Abstract
Background: Aberrant promoter DNA methylation has been reported in childhood acute lymphoblastic leukaemia 
(ALL) and has the potential to contribute to its onset and outcome. However, few reports demonstrate consistent, 
prevalent and dense promoter methylation, associated with tumour-specific gene silencing. By screening candidate 
genes, we have detected frequent and dense methylation of the TESTIN (TES) promoter.
Results: Bisulfite sequencing showed that 100% of the ALL samples (n = 20) were methylated at the TES promoter, 
whereas the matched remission (n = 5), normal bone marrow (n = 6) and normal PBL (n = 5) samples were 
unmethylated. Expression of TES in hyperdiploid, TEL-AML+, BCR-ABL+, and E2A-PBX+ subtypes of B lineage ALL was 
markedly reduced compared to that in normal bone marrow progenitor cells and in B cells. In addition TES methylation 
and silencing was demonstrated in nine out of ten independent B ALL propagated as xenografts in NOD/SCID mice.
Conclusion: In total, 93% of B ALL samples (93 of 100) demonstrated methylation with silencing or reduced expression 
of the TES gene. Thus, TES is the most frequently methylated and silenced gene yet reported in ALL. TES, a LIM domain-
containing tumour suppressor gene and component of the focal adhesion complex, is involved in adhesion, motility, 
cell-to-cell interactions and cell signalling. Our data implicate TES methylation in ALL and provide additional evidence 
for the involvement of LIM domain proteins in leukaemogenesis.
Background
Methylation of gene promoters is a mechanism by which
tumour suppressor genes can be inactivated. The role of
promoter methylation in carcinogenesis has been con-
vincingly demonstrated when gene methylation consti-
tutes one of two events causing inactivation of well-
documented tumour suppressor genes. Examples
include, familial stomach cancer in which the non-
mutated allele of CDH1 is silenced by promoter methyla-
tion [1] and sporadic renal cell cancer and retinoblastoma
in which the non-deleted alleles of VHL and RB respec-
tively are silenced [2,3].
Distinction of genes whose methylation is causally
associated with malignant transformation from those
that are affected by non-specific methylation remains
problematic. It is plausible that genes that are densely
methylated in all cells within the leukaemic clone are
more likely to be involved in tumourigenesis than those
that are partially methylated in a low proportion of leu-
kaemic cells. Also genes that are methylated in a high
proportion of cases seem more likely to be pathogenically
important. Parallel evidence of gene silencing and evi-
dence that the affected gene is a tumour suppressor gene
greatly strengthens the case for a causal role in tumouri-
genesis.
Promoter methylation can occur as a non-specific
"bystander" event affecting genes that are already silent in
non-malignant tissue. For example, Keshet et al. reported
that of 106 genes whose promoters were methylated in
colon cancer cell lines, 91 were already inactive in normal
colon [4]. Similarly, in acute lymphoblastic leukaemia
(ALL), the methylated gene TIMP3 was not expressed
regardless of its methylation status [5].
Gene promoter methylation has been reported for an,
as yet, small number of genes in ALL [5-9]. Genes that are
reported to be methylated in ALL are involved in many
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cellular processes including growth regulation, apoptosis,
cell adhesion, and others [6,8,9] and therefore gene
silencing by methylation is hypothesised to be an impor-
tant contributor to leukaemogenesis. An example of can-
didate epigenetic silencing in the initiation and
progression of leukaemogenesis involves CDKN2B. This
region frequently undergoes loss of heterozygosity (LOH)
in ALL [10,11]. Dynamic changes of CDKN2B promoter
methylation have been reported during human myeloid
development [12] suggestive of a role in normal hae-
matopoiesis.  CDKN2B  promoter methylation, detected
by methylation specific PCR, has been repeatedly
reported in ALL leading to claims that this methylation in
involved in leukaemogenesis [13-16]. However, CDKN2B
methylation was neither dense, clonal nor prevalent in
the reported cases.
For most of the reported gene methylation events in
ALL, the proportion of affected cells and the density of
methylation have not been quantified. For example, posi-
tivity in a methylation specific PCR assay indicates the
presence of methylated alleles, but not their relative pro-
portions. Array based methods, although not quantita-
tive, have also been used to screen for methylated genes
[7].
Methylation-specific multiplex ligation-dependent
probe amplification (MS-MLPA), a modification of
MLPA, was developed as a tool for quantifying methyla-
tion at CpG sites located at methylation-sensitive restric-
tion sites, by including a digestion step with a
methylation-sensitive restriction enzyme such as HhaI
[ 1 7 ] .  M L P A  c a n  a l s o  b e  u s e d  t o  m e a s u r e  g e n e  d o s e .
Therefore, MS-MLPA allows the rapid, simultaneous
analysis of both copy number and methylation at a num-
ber of gene promoters. Here we use MS-MLPA to quan-
tify methylation of candidate tumour suppressor genes in
paediatric ALL.
Results
TES methylation and expression in ALL bone marrow 
samples
To identify genes showing frequent high-level methyla-
tion, DNA from five ALL marrow samples and one
peripheral blood sample were analysed. The density of
methylation within 24 gene promoter regions was deter-
mined by using MS-MLPA, in multiple independent
experiments. Percent methylation at the HhaI site was
calculated by comparing normalised, HhaI-digested peak
areas to normalised, mock-digested peak areas.
Of the genes examined, the TES promoter was the most
frequently methylated, with four out of five ALL samples
showing a high percentage of methylation. At the interro-
gated site, the percent methylation was 96, 76, 80, 75 and
7% for cases 1-5 respectively (normal PBL had 2.5%
methylation).
To validate the MS-MLPA results, detailed analysis of
TES promoter (Additional file 1, Figure S1) methylation
was obtained by performing bisulfite sequencing. ALL
DNA samples and normal PBL DNA were bisulfite
treated, amplified using bisulfite-specific primers, cloned
and sequenced. Each of the ALL samples was hypermeth-
ylated compared to peripheral blood (Figure 1A). ALL5
(T lineage; Age: 7 years 7 months), for which methylation
was not detected by MS-MLPA, showed the lowest level
of methylation, but was methylated at CpG sites other
than the HhaI site interrogated by MS-MLPA.
Bisulfite sequencing was then performed on a larger
group of samples including normal peripheral blood, nor-
mal bone marrow, additional ALL bone marrow samples
and remission bone marrow samples. Normal peripheral
blood (n = 5; Figure 1B) and bone marrow (n = 6; data not
shown) samples showed no methylation of the TES pro-
moter. Leukaemia DNA, but not matched remission sam-
ples showed methylation of the TES promoter (Figures
1C and 1D). In summary, twenty out of twenty ALL sam-
ples were hypermethylated compared to normal blood
and bone marrow at the TES promoter. Five of the ALL
samples showed a small number of completely unmethy-
lated alleles. These alleles could reflect the presence of a
population of non-malignant cells in the marrow aspirate
sample. For ALL samples, the percentage of methylation
for all sites in the promoter ranged from 11% to 86% with
a median of 65% and an interquartile range of 50-74%. In
particular, B ALL samples had median methylation of
71% (interquartile range of 64-77%), whilst the T ALL
samples (ALL5, ALL13 (6 years 1 month) and ALL15 (5
years 3 months)) had median methylation of 32.9% (B
ALL vs. T ALL: p < 0.01 by T test). In contrast the per-
centage methylation with peripheral blood ranged from 0
to 1.5%. Since the amplification and cloning of bisulfite-
treated DNA is subject to biases, the results are only
semi-quantitative.
To confirm that the observed hypermethylation did not
reflect preferential cloning biases within the bisulfite con-
version-derived PCR products, we developed a combined
bisulfite restriction assay (CoBRA). After bisulfite con-
version, reverse strand amplification of fully methylated
DNA generates four TaqαI sites (TCGA) at CpG sites 3,
10, 16 and 30, whereas none are present in unmethylated
DNA after amplification. CoBRA was performed on six
ALL samples, one matched remission and one normal
PBL sample. In all cases, the validity of the bisulfite
sequencing results was confirmed by the CoBRA analysis
(Figure 2). For example, ALL8 (B lineage; 5 years 9
months) and ALL12 (B lineage; 5 years), which show
dense methylation by bisulfite sequencing (Figure 1C),
showed a CoBRA banding pattern indicative of dense
methylation. Similarly, the partial methylation shown by
ALL19 (B lineage; 6 years 3 months) (Figure 1D) is paral-Weeks et al. Molecular Cancer 2010, 9:163
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leled by a CoBRA banding pattern indicative of partial
methylation at CpG10 and CpG16. The unmethylated
remission and normal PBL were undigested by TaqαI, also
in agreement with bisulfite sequencing results.
The presence of SNPs (rs1319886, rs28411392 and
rs11549785) in the TES promoter permitted analysis of
allele-specific methylation. Bisulfite sequencing of the
reverse strand confirmed biallelic methylation in five
informative ALL samples (Table 1). Additionally the pres-
ence of another promoter SNP (rs11549786), outside of
the bisulphite PCR amplicon, and of a telomeric micro-
satellite (D7s655) permitted copy number analysis. In 15
out of 20 cases LOH was excluded, but in the remaining 5
non-informative cases LOH could not be excluded.
TES mutations have been reported in T ALL (CCRF-
CEM), breast cancer and ovarian cancer cell lines [18,19]
and we hypothesised that the less methylated ALL sam-
ples may contain coding mutations. Exon sequences from
ALL5 and ALL19 (the two samples with the lowest den-
sity of methylation) were amplified and sequenced. No
mutations were found (data not shown), however we
were unable to exclude the possibility of intragenic dele-
tions not readily detectable by amplification and
sequencing.
TES promoter methylation has been shown to down-
regulate expression in breast cancer cell lines, leukaemia
cell lines [18] and glioblastomas [20]. To determine the
role of methylation on TES expression in ALL we used
microarrays to compare expression in a separate cohort
of paediatric precursor B ALL specimens with two con-
trol precursor cell populations, normal bone marrow
CD34+ progenitor cells (n = 5) and umbilical cord blood
CD19+IgM- (pre-B) cells (n = 3). Leukaemia samples
Figure 1 Methylation plots for ALL bone marrow and normal PBL DNA. Bisulfite sequencing of ALL marrow, remission marrow and normal PBL 
samples; each horizontal grouping indicates one sequenced clone, individual circles represent each CpG site (open circles and closed circles represent 
unmethylated and methylated CpG sites respectively). A. Methylation plots of ALL samples initially assayed by MS-MLPA. B. Normal PBL DNA methy-
lation plots. C. Further ALL methylation plots. D. Matched ALL and remission methylation plots. Dotted line indicates location of HhaI site used in MS-
MLPA. Percent methylation is shown in parentheses.
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were classified into subtypes using expression profiling
based on Yeoh et al. [21].
As previously reported, in a comparison of gene expres-
sion between normal bone marrow CD34+ cells and pre-
cursor B ALL, TES was among the most down-regulated
genes as assessed by Affymetrix HG-U133A microarrays
[22]. Under a linear regression model a marked reduction
in relative expression of TES (probe-set 202719_s_at) was
observed in the common subtypes of precursor B ALL,
including hyperdiploid, TEL-AML1, BCR-ABL, E2A-
PBX1 (for each subgroup p < 0.001) and in T lineage ALL
(p < 0.05) but not in MLL rearranged ALL (p = 0.20),
when compared to CD34+ BM (Figure 3). Similar p-val-
ues were recorded when CD19+ CB was used as the com-
parison or if the second TES probe-set (202120_at) was
used, though p-values were not always as strong. In total
marked reduction in TES expression was observed in 68
of the 74 cases of B ALL (Figure 3).
TES methylation and expression in leukaemia cell lines
The relationship between TES expression and methyla-
tion was examined directly in available leukaemia cell
lines. DNA methylation status was determined using
CoBRA as before (Figure 4A). In brief, MOLT4 (T ALL)
bisulfite-specific PCR product was completely digested
by TaqαI, indicating that MOLT4 cells are methylated at
the four CpG sites interrogated by TaqαI. Raji (Burkitt
lymphoma) cells appear to be hemi-methylated, i.e.,
methylated on one allele and unmethylated on the other
allele. RT-PCR was performed on total cell line RNA
using exon-specific primer pairs. PCR products from
amplifications with primers spanning exon 3 and exon 6
are shown (Figure 4B). TES expression was present in Raji
and normal PBL, but was undetectable in MOLT 4 cells
by RT-PCR. Also, TES expression levels were quantified
using real-time quantitative RT-PCR (qRT-PCR) with
expression levels calculated relative to normal PBL levels
after normalisation to β2-microglobulin and reproduced
on Figure 4B. TES promoter methylation resulted in a
reduction of TES expression in the leukaemia cell lines
tested in agreement with previously published reports
[18,20].
To confirm the inverse relationship between methyla-
tion and expression, CoBRA and qRT-PCR was per-
formed on TES  expressing, myeloid-lineage cell lines:
HL60, K562 and U937. Bisulfite-specific PCR products
from HL60, K562 and U937 cells were not digested by
TaqαI, thus demonstrating the inverse relationship
between methylation and expression.
As previously reported [18] multiple splice variants of
TES were detectable by RT-PCR; however an unexpected
splice variant was amplified from both cell lines and nor-
mal blood (Figure 4B). This novel splice variant was
sequenced and compared with published variants. The
novel variant cDNA uses a cryptic splice site present in
exon 5 to generate a 102 bp shorter cDNA product, which
if translated would result in a truncated protein of 237
amino acids (see Additional file 2, Figure S2).
TES silencing in ALL xenografts
Next, fourteen ALL xenografts [23] were analysed for
TES  promoter methylation and expression analysis.
Methylation status was measured by CoBRA assay and
was in complete, reciprocal agreement with expression
l ev e l s  m eas u r ed  b y  r e a l  t i m e  R T - PCR  ( see  F i gu r e  4 C ) .
Without knowledge of their phenotypes, we predicted
that almost all methylated and non-expressing xenografts
would be B-lineage derived, whereas unmethylated and
TES  expressing xenografts would be T-lineage ALL.
xALL 2, 3, 4, 7, 8, 10, 11, 19 and 30 were predicted to be
B-lineage: this was correct except for xALL 30 which was
T ALL. xALL 16, 17, 27, 29 and 31 were predicted to be T
ALL: xALL 16, 27, 29 and 31 were confirmed to be T-lin-
eage ALL, whereas xALL 17 was B-lineage [23]. Analysis
of the karyotype of xALL 17 (46, XX, -20, +21 (18), XX, -
20, +21, +mar (4)) suggests that xALL 17 be classified as
"Other" according to Yeoh et al. [21] (see Figure 3). Of the
TES-expressing xenografts, xALL31 appeared to show
hemi-methylation of the TES promoter with 50% of the
bisulfite-specific PCR product not being digested by
TaqαI .  T h i s  h e m i - m e t h y l a t i o n  w a s  s i m i l a r  t o  t h a t  s e e n
with the Raji cell line (see Figure 4A). In conclusion, we
were able to predict the lineage of ALL xenografts on the
basis of TES expression and methylation.
We have demonstrated TES hypermethylation in 17 of
17 B ALL samples using bisulfite sequencing and down-
regulation of TES expression using expression profiling in
Figure 2 CoBRA of ALL bone marrow DNA. A. Diagram of reverse-
strand bisulfite-specific PCR fragment showing location of potential 
TaqαI restriction sites (T). B. TaqαI digests of TES bisulfite-specific PCR 
products from normal PBL, ALL and remission samples. Fully methylat-
ed DNA will generate fragments of 161, 109, 26, 39 and 42 bp respec-
tively. (Marker lane; 100, 200, 300, 400 and 500 bp bands; U - 
undigested PCR product).
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Table 1: Summary of leukaemia methylation and LOH status in ALL bone marrow aspirates
Bisulfite-specific data Genomic DNA
Bisulfite (rev) SNPa Biallelic Methylation D7s655b Genotype SNPc LOHd Notes
ALL1 2 C/T, C/T, C/T, A N Same as remission
ALL2 GAG 2 C, T, C, A N
ALL3 GAG, AAG Y 1 C, T, C/T, A N Same as remission
ALL4 1 C/T, C/T, C/T, A N
ALL5 1 C, T, C/T, A N
ALL6 2N
ALL7 2N
ALL8 GAG, AAG Y 1 N
ALL9 GGA, AAG Y N
ALL10 GAG, GGA Y N
ALL11 2N
ALL12 GAG 2 N
ALL13 LOH?
ALL14 2N
ALL15 1N o n - I n f o r m a t i v e
ALL16 AAG LOH?
ALL17 Non-Informative LOH?
ALL18 GGA, GAG Y 1 C/T, C/T, C, A N Same as remission
ALL19 GGA Non-Informative Same as remission
ALL20 GGA 1 Non-Informative LOH?
a SNP data (rs1319886, rs2811392, rs11549785) generated from bisulfite sequencing. bNumber of alleles at D7s655 microsatellite. cSNP data 
(rs11549786, rs11549785, rs2811392, rs1319886) generated from promoter sequencing. d Summary of loss of heterozygosity status.Weeks et al. Molecular Cancer 2010, 9:163
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68 of 74 independent B ALL samples. In addition, we
have demonstrated both promoter methylation and
silencing of TES expression in 8 of 9 B ALL xenografts. In
total, transcriptional silencing and/or promoter methyla-
tion of TES occurred in 93 of 100 B ALL and 20 of 28 T
ALL cases.
Discussion
This study demonstrates that the TES  promoter is
densely methylated in a high proportion of childhood
ALL. Eighteen of twenty tested leukaemia bone marrow
aspirate samples were densely methylated at the TES pro-
moter, whereas matched remission marrow, normal
peripheral blood and bone marrow samples were unm-
ethylated. In addition, eight of nine B-lineage ALL xeno-
graft samples showed dense methylation of the TES
promoter. The proportion of ALL cases that showed
methylation of TES is among the highest for any genes
reported to date [6] and similar to levels reported by Hes-
son et al. [24] and Taylor et al. [7]. Taylor et al. found
methylation in DCC in 9 of 10 cases of precursor B ALL
and in RUNDC3B,  KCNK2, and DLC1  in 7, 7 and 8
(respectively) of these 10 cases [7]. And in a recent study,
Hesson et al. reported RASSF6 promoter methylation in
48 of 51 B ALL and 12 of 29 T ALL cases [24]. For com-
parison, some of the genes that are commonly referred to
as methylated in ALL, e.g. the p15 promoter have shown
methylation of only 18% of alleles [6].
TES is located in 7q31.2, a region showing frequent loss
of heterozygosity in myeloid malignancies [25] (between
D7S2554 and D7S2460). In addition, loss of heterozygos-
ity at 7q31 occurs in gastric cancer [26], prostate cancer
[27], breast cancer [28] and others (see Tobias et al. for an
overview [19]). The frequent LOH implies the presence
of at least one tumour suppressor gene, although the
absence of mutations in candidate genes has led to sug-
gestions that regulatory gene(s) within the region might
be inactivated by epigenetic mechanisms [29,30]
TES is a putative tumour suppressor gene. Drusco et al.
concluded that TES acted as a tumour suppressor gene in
vivo, given that TES knockout mice showed an increased
susceptibility to carcinogen (nitrosomethylbenzylamine)
- induced gastric cancer [31]. In addition, restoration of
TES by adenoviral transduction of non-TES expressing
breast cancer and uterine sarcoma cell lines inhibited
their growth by induction of apoptosis [32]. Additionally
the tumourigenic potential of these transduced cell lines
was significantly reduced in nude mice. Furthermore,
forced TES expression in a non-expressing, invasive duc-
tal breast carcinoma cell line had an inhibitory effect on
proliferation, on anchorage-independent growth in aga-
rose and on colony forming ability [33].
Available evidence suggests that apart from deletion,
the commonest mechanism of TES inactivation is epige-
netic.  TES  methylation has been shown in primary
tumours, including glioblastomas (18 of 31) [20] and
ovarian cancer [19]. Methylation at a single site in the
TES  promoter has been reported for several cell lines
including lymphoid leukaemia, breast cancer and pancre-
atic cancer cells [18]. TES methylation is closely associ-
ated with loss of TES expression in cell lines [18] and in
glioblastoma cells [20]. By using xenograft and immortal-
ised leukaemia cell lines, we have now directly demon-
strated the reciprocal relationship between methylation
and expression.
In contrast to epigenetic inactivation, TES mutations
have been reported in only three cell lines [18,19]. We
investigated whether ALL5 and ALL19 (both partially
methylated) harboured mutations; however TES coding
mutations were not detected by exon sequencing.
We confirmed that there is substantial down-regulation
of TES expression in an independent cohort of ALL cases
and in B ALL xenografts. The marked down-regulation of
TES in virtually all cases of ALL, compared to normal
precursor cells, indicates that TES  methylation sup-
presses expression that is present in relevant precursor
cells. Although TES expression levels were not confirmed
in these ALL cases, we had previously demonstrated
excellent correlation between these array results and
qRT-PCR measurements for the majority (33/48) of
selected genes [34]. Additionally, our array results show
consistent down-regulation with both TES  - specific
probes used. Importantly another published series of 87
cases of B-lineage ALL showed that TES was downregu-
lated compared to normal bone marrow and normal hae-
Figure 3 TES expression levels in ALL subgroups. TES expression in 
102 independent ALL samples was assayed using Affymetrix HG-
U133A microarray. TES expression was calculated for both TES-specific 
probes (probe 202719_s_at (lower) is located in TES coding sequence 
and probe 202720_s_at (upper) is located in the 3' UTR). A horizontal 
line indicates the median TES expression for each sub-group. (* Indi-
cates significance (p < 0.01) to CD34+ median expression; ? indicates 
significance (p < 0.01) to CD19+ median expression)
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matopoietic cells, being the second most highly ranked
down-regulated gene [35]. Furthermore, within the
cohort of Ross et al., TES showed substantial down-regu-
lation in B-lineage ALL compared to MLL-translocation
ALL, or T-cell ALL [36].
TES, a highly conserved protein (Additional file 3, Fig-
ure S3), is composed of three C-terminal LIM domains
and a PET (prickle, espinas and testin) domain of
unknown function. LIM domains are 50-60 amino acids
in size and are believed to be involved in protein-protein
interactions. LIM-domain containing proteins are classi-
fied into 4 groups; groups 2, 3 and 4 being predominantly
localised to cytoskeleton-associated structures including
focal adhesion complexes, whereas group 1 LIM proteins
are predominantly nuclear.
TES, a group 3 LIM domain protein, is a component of
the focal adhesion complex and localises to cell-matrix
adhesions, cell-cell contacts and to actin stress fibres. In
mice, Tes has been shown to interact or colocalise with
cytoskeletal proteins including actin, zyxin, Mena, VASP,
talin, α-actinin, and paxillin [37]. Tes recruitment to the
focal adhesion complex appears to be mediated by zyxin
through the LIM1 domain [33]. Tes also binds Mena,
which inhibits Mena's ability to interact with FPPPP-
motif proteins, such as zyxin, thus displacing Mena from
focal adhesion complexes [38]. Over-expression of TES
leads to loss of Mena from focal adhesions, increased cell
spreading and decreased cell motility [37-40]. This sug-
gests that Tes downregulates Mena-dependent cell motil-
ity, implying that loss of Tes might enhance cell mobility
[38]. As haematopoietic development requires coordi-
nated bone marrow retention, adhesion and cell migra-
tion [41], we suggest that silencing of TES  might
contribute to ALL by interfering with normal interactions
Figure 4 TES methylation and expression in cell lines and xenografts. A. TaqαI digests of TES bisulfite-specific PCR products from cell lines HL60, 
K562, MOLT4, Raji and U937, and normal PBL. B. Amplification of cell lines and normal PBL samples cDNAs using primers specific for TES exon 3 (5' 
TGCAAGTGTGGCCAAGAAGAGC 3') and exon 6 (5' CAGCGTGATTCTTCACATAGCAGG 3') and β2-microglobulin (For: 5' GAGTATGCCTGCCGTGTG 3' and 
Rev: 5' AATCCAAATGCGGCATCT 3'); first strand cDNA, with (+) or without (-) Superscript III reverse transcriptase. TES expression levels relative to PBL 
expression after normalisation to β2-microglobulin were calculated using qRT-PCR and are shown. C. qRT-PCR was used to calculate TES expression 
levels in ALL xenografts relative to PBL expression after normalisation to β2-microglobulin expression. Methylation status was determined using CoBRA.
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and adhesion between progenitors and stroma, with
increased motility of immature progenitors, resulting in
premature release of progenitors from bone marrow
niches.
Additionally, TES has been detected in the nucleus,
specifically the nucleolus, and the endoplasmic reticulum
[42]. It is proposed that the nucleolar localisation involves
an alternative, closed confirmation state in which the N-
terminus binds to the third LIM domain of TES [42].
Therefore TES, similar to many of the other cytoplasmic
LIM proteins, may shuttle into, and have a functional role
within the nucleus. The possibility of additional complex-
ity in the functional roles of TES is raised by our identifi-
cation of a previously unreported short transcript of TES
in normal cells. If translated, this truncated protein would
be very similar to the LIM-less TES proteins designed by
Coutts et al. [37]. These LIM-less TES proteins do not
localise to focal adhesions but are found associated with
actin stress fibres. The function of the LIM-less splice
variant is unknown, but it may compete with full-length
TES activity.
Interestingly, other LIM domain proteins have been
implicated in leukaemogenesis. For example, the group 1
nuclear-localised LIM protein LMO2 acts as an onco-
genic protein in T-cell ALL [43]. The role of LMO2 in
oncogenesis was also demonstrated in two separate gene
therapy trials for X-linked SCID, which were halted when
five (out of 19) patients developed leukaemia. Remark-
ably four of the patients had insertion of the therapeutic
retrovirus upstream of the LMO2 locus with subsequent
over-expression of the LMO2 gene [44]. LMO2 appears
to act as a bridging molecule to assemble haematopoietic
transactivating complexes and is essential for develop-
ment of haematopoietic lineages [45].
Conclusions
The current study shows that dense methylation of the
TES promoter, resulting in loss of TES expression is prev-
alent in childhood ALL. Indeed, TES has been shown to
be either methylated or silenced in 93% of B ALL (93 of
100) tested; thus TES is the most common (epi)genetic
abnormality in B ALL. In addition a recent study reports
TES as one of 36 genes showing hypermethylation and
reduced expression in ETV6/RUNX1-positive and hyper-
diploid subtypes of B ALL [9]. Based on the known func-
tions of TES, we predict consequent aberrant adhesion
between progenitors and bone marrow stroma, which we
hypothesise contributes to leukaemia initiation and pro-
gression. Evidence that TES, like other LIM proteins, is
shuttled to the nucleus and the presence of additional
transcripts of TES, invoke the possibility that the tumour
suppressing functions of TES may reside within alterna-
tive functions that are yet to be determined.
Methods
ALL samples
Paediatric acute lymphoblastic leukaemia (n = 20) and
matched remission (n = 5) bone marrow aspirate sam-
ples, normal marrow and normal peripheral blood leuko-
cyte (PBL) samples were collected in accord with ethical
approval obtained from the Otago Ethics Committee. All
samples contained at least 80% blasts, and usually at least
90%. The remission samples that were used were
obtained at least 35 days after diagnosis. The median age
of the ALL patients was 4 years 10 months (range 2 years
to 11 years 3 months), and comprised 17 B lineage and 3
T lineage (ALL5, ALL13 and ALL15) ALL. Samples were
obtained prior to routine molecular testing; two B lineage
cases showed a hyperdiploid karyotype (ALL11 and
ALL14); one B lineage case (ALL2) had t(9;22) and no
cases showed structural 11q23 abnormalities (MLL gene
location).
Cell lines were newly obtained from the American Type
Culture Collection (ATCC, Manassas, VA, USA) and
maintained according to ATCC instructions.
A separate group of ALL samples were maintained as
xenografts in SCID/NOD mice as previously described
[23].
Multiplex Ligation-dependent Probe Amplification assay
Twenty-four candidate genes were chosen from pub-
lished literature. At the time of selection (2005) these
candidates included the majority of genes known to be
methylated in haematopoietic cancers.
MS-MLPA probes were designed to interrogate HhaI
sites within the reported region of methylation and pur-
chased from Sigma-Proligo (St Louis, MO, USA)(see
Additional file 4, Table S4). The 24 HhaI site containing
probes and three control probes were prepared as three
separate probe-mixes and used with the MLPA EK1 kit
(MRC Holland, Amsterdam, The Netherlands). MS-
MLPA assays were performed as per manufacturer's
instructions. After probe ligation each sample was
divided in two, with one aliquot being incubated with
HhaI. Ligated probes were then amplified using MLPA-
universal primers and products were detected with an
ABI3100 capillary sequencer, and analysed using GENES-
CAN (Applied Biosystems Ltd, Foster City, CA, USA) and
EXCEL (Microsoft, Redmond, WA, USA) software.
Three control probes, not digested by HhaI, were used for
normalisation of probe peak areas.
Each probe peak area was normalised using the sum of
the control probe peak areas. Percent methylation was
calculated from the normalised HhaI-digested peak area
and the normalised mock-digested peak area (as below).
norm peak area
probe peak area
control peak areas
  
  
  
=
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Bisulfite Sequencing
DNA from ALL and matched remission samples, normal
PBL and bone marrow samples were bisulfite-treated
using either the EZ DNA Methylation Gold system
(Zymo Research, Orange, CA, USA) or our standard
bisulfite-treatment protocol [46].
Bisulfite-specific primers were designed using the
MethPrimer website [47] (Forward: 5' TTAGGGTTATT-
GAGTTTGTTTAGTAGG 3'; Reverse: 5' CTTTATTTTC-
CAAATCCATATTAAC 3'), and were used to amplify 371
base pairs or 48 CpG dinucleotides of the TES promoter.
Amplified products were cloned using TOPO TA Clon-
ing system (Invitrogen, Carlsbad, CA, USA) and
sequenced using ABI BigDye 3.1 Terminator System and
supplied TOPO M13 reverse primer. Resulting sequences
were viewed and, if necessary, edited in 4 Peaks http://
mekentosj.com/4peaks/, and aligned using the Se-Al
v2.0a11 Carbon program http://evolve.zoo.ox.ac.uk/. Per-
cent methylation was calculated as the percentage of
methylated CpGs out of total CpGs sequenced.
Genotyping
Amplification of genomic DNA was performed using
TES promoter-specific primers (Forward: 5' ACCAGGT-
CAGGGTCACTGAGCTTGC 3'; Reverse: 5' ACCCGCG-
CAGGTGAAGCAGC  3') to investigate four SNPs
(rs11549786, rs11549785, rs28411392 and rs1319886).
PCR products were purified using DNA Clean-Up kit
(Zymo Research) and sequencing was performed as
above, using genotyping PCR primers.
Combined Bisulfite Restriction Assay (CoBRA)
CoBRA was designed to interrogate four TaqαI sites gen-
erated from methylated DNA after bisulfite conversion.
DNA was bisulfite-treated and amplified using primers
designed to the reverse strand (Forward: 5'ATTTT-
GTTTTTTAGGTTTATGTTAA 3'; Reverse: 5' CCAAAT-
CAAAATCACTAAACTTACC  3'). After PCR amplific-
ation and DNA Clean-Up (Zymo Research), purified
products were digested with T aq αI and electrophoresed
through 2% Seakem LE agarose (Lonza, Basel, Switzer-
land). Amplified products were cloned and sequenced as
above, to generate SNP genotyping data.
Microarray Gene expression
Total RNA was extracted from 101 bone marrow speci-
mens from paediatric ALL patients, from five isolates of
CD34+ cells from normal marrow, and from three iso-
lates of CD19+IgM- cells from umbilical cord blood as
previously described [22]. cRNA was prepared and hybri-
dised to HG-U133A microarray (Affymetrix, Santa Clara,
CA, USA) as described [22]. ALL samples were classified
into leukaemia sub-groups, as described by Yeoh et al.
[21]. TES expression was calculated from both TES-spe-
cific probes and median expression level for each ALL
sub-group was calculated.
Reverse Transcriptase PCR
First strand cDNA was generated from total RNA using
Superscript III Reverse Transcriptase (Invitrogen) and
manufacturer's instructions, except a mix of oligo-dT and
random primers were used to prime the synthesis. Multi-
ple exon-specific primers were designed to amplify
cDNA, with genomic DNA not being amplified or pro-
ducing larger sized products. RT-PCR products were
cloned using the TOPO TA Cloning System before being
sequenced. TES expression levels were measured using
ABI Assay-On-Demand kits (TES: Hs_00932509_g1; β2-
microglobulin: Hs00984230_m1) and ABI PRISM 7900
HT Sequence Detection System (Applied Biosystems Ltd)
according to manufacturer's instructions. TES expression
levels were normalised to β2-microglobulin before calcu-
lation relative to normal PBL levels.
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Additional file 1 Figure S1: TES promoter CpG island sequence. TES 
promoter CpG island sequence showing the location of 48 CpG sites (num-
bered), the translation start site (arrow) and three SNPs (rs1319886, 
rs2811392 and rs11549785). MS-MLPA interrogated HhaI restriction site is 
underlined.
Additional file 2 Figure S2: Splice variant sequence. Alignment of TES 
cDNA region (exon 3 to exon 6) (GenBank ID AK222840; upper) with PCR-
generated splice variant (GQ423971; lower); the missing 102 bp fragment 
and predicted, truncated protein sequences are shown. Primer sequences 
are shown underlined and exon splice sites are indicated by a hyphen.
Additional file 3 Figure S3: Alignment of TES proteins. Human TES pro-
teins aligned with TES proteins of other species. PET and LIM domains are 
indicated.
Additional file 4 Table S4: MS-MLPA probe sequences.Weeks et al. Molecular Cancer 2010, 9:163
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